Bionime (TPE:4737) Cyclically Adjusted Revenue per Share: NT$33.53 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4737 Bionime Corp TPE:4737
65 GF Score
Price NT$55.40
GF Value NT$58.69
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Cyclically Adjusted Revenue per Share?

Bionime TPE:4737 -1.60% 65 Cyclically Adjusted Revenue per Share is NT$33.53 as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.69 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bionime's adjusted revenue per share for the three months ended in Dec. 2025 was NT$6.288. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$33.53 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Bionime's average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bionime was 2.70% per year. The lowest was -0.90% per year. And the median was 1.75% per year.

As of today (2026-07-24), Bionime's current stock price is NT$55.40. Bionime's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$33.53. Bionime's Cyclically Adjusted PS Ratio of today is 1.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bionime was 2.47. The lowest was 1.34. And the median was 1.93.


Bionime  (TPE:4737) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bionime's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=55.40/33.53
=1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bionime was 2.47. The lowest was 1.34. And the median was 1.93.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bionime Cyclically Adjusted Revenue per Share Related Terms


Bionime Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bionime's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Cyclically Adjusted Revenue per Share Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.69 34.40 33.94 33.71 33.53

Bionime Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.71 33.98 34.10 34.00 33.53

TPE:4737 vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Bionime's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionime Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bionime's Cyclically Adjusted PS Ratio falls into.


TPE:4737
65GF Score
Bionime Corp TPE:4737
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bionime's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=6.288/324.0540*324.0540
=6.288

Current CPI (Dec. 2025) = 324.0540.

Bionime Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 4.742 238.132 6.453
201606 6.134 241.018 8.247
201609 6.279 241.428 8.428
201612 7.394 241.432 9.924
201703 5.438 243.801 7.228
201706 6.374 244.955 8.432
201709 6.758 246.819 8.873
201712 8.925 246.524 11.732
201803 6.012 249.554 7.807
201806 6.849 251.989 8.808
201809 8.706 252.439 11.176
201812 9.566 251.233 12.339
201903 5.678 254.202 7.238
201906 8.853 256.143 11.200
201909 7.539 256.759 9.515
201912 10.951 256.974 13.810
202003 5.445 258.115 6.836
202006 5.665 257.797 7.121
202009 6.691 260.280 8.330
202012 7.539 260.474 9.379
202103 6.848 264.877 8.378
202106 6.174 271.696 7.364
202109 7.300 274.310 8.624
202112 7.137 278.802 8.295
202203 7.022 287.504 7.915
202206 8.418 296.311 9.206
202209 8.394 296.808 9.165
202212 8.702 296.797 9.501
202303 6.159 301.836 6.612
202306 6.189 305.109 6.573
202309 6.432 307.789 6.772
202312 7.022 306.746 7.418
202403 6.930 312.332 7.190
202406 7.042 314.175 7.263
202409 7.186 315.301 7.385
202412 7.409 315.605 7.607
202503 7.101 319.799 7.195
202506 6.909 322.561 6.941
202509 6.754 324.800 6.738
202512 6.288 324.054 6.288

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$33.53 mean?
Bionime (TPE:4737) has a Cyclically Adjusted Revenue per Share of NT$33.53 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bionime and its competitors.
Is Bionime's Cyclically Adjusted Revenue per Share too high?
Bionime's current Cyclically Adjusted Revenue per Share is NT$33.53. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Bionime's Cyclically Adjusted Revenue per Share of NT$33.53 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bionime and its competitors. Bionime's current Cyclically Adjusted Revenue per Share is NT$33.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.69, compared to a current price of NT$55.40 — trading 5.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$33.53. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bionime (TPE:4737), the current Cyclically Adjusted Revenue per Share is NT$33.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$55.40 is trading 5.6% below its estimated GF Value™ of NT$58.69. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Cyclically Adjusted Revenue per Share: NT$33.53
  • GF Value™: NT$58.69 vs. price of NT$55.40 (5.6% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score

Get the complete analysis for TPE:4737

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$55.40
Price
NT$58.69
GF Value